Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Pullback

Event overview and recent stock context

Agios Pharmaceuticals (AGIO) has drawn attention after a recent share price pullback, with the stock down about 22% over the past month and modestly negative over the past 3 months.

See our latest analysis for Agios Pharmaceuticals.

That recent 22% one month share price pullback comes after a relatively flat 90 day share price return of about 1% decline and a modestly positive year to date share price return of 1.4%. At the same time, the 1 year total shareholder return of 8% decline and 5 year total shareholder return of 51% decline suggest long term holders have faced pressure, so recent momentum looks fragile rather than firmly rebuilding.

If this kind of volatility has you comparing opportunities, it can be helpful to see what else is moving in related areas of the market, starting with 33 healthcare AI stocks.

With Agios trading at $27.56, recent losses, ongoing net income of $422.603 million loss, and a relatively low value score of 2, you have to ask: is the weakness already reflected in the price, or is the market quietly expecting stronger growth ahead?

Most Popular Narrative: 34% Undervalued

Agios Pharmaceuticals last closed at $27.56, while the most followed narrative puts fair value at $41.50 using a 7.1% discount rate. The gap between price and narrative expectations is wide.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios’ addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Read the complete narrative.

Want to see what kind of revenue ramp and future margins sit behind that fair value gap? The narrative leans on rapid top line expansion and a rich future earnings multiple to bridge today’s losses with tomorrow’s potential cash flows.

Result: Fair Value of $41.50 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could change quickly if PYRUKYND faces regulatory setbacks around safety, or if high R&D and SG&A costs keep net losses elevated.

Find out about the key risks to this Agios Pharmaceuticals narrative.

Another valuation lens: rich sales multiple against peers

The narrative fair value of $41.50 leans on future cash flows, but today the stock trades on a P/S of 24.8x. That is more than double the US Biotechs average of 11x and far above the peer average of 3.2x, while the fair ratio points to 0x. Is the market overpaying for growth that might take longer to show up?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, and with both concerns and reasons for optimism in play, it makes sense to check the details yourself and decide how the trade off looks. To see both sides of the story in one place, review the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Agios is only one piece of your watchlist, now is the moment to broaden your options and compare it with other stocks that fit clear, disciplined criteria.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com